ABBVIE (ABBVIE) News
Follow ABBVIE (ABBVIE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
AbbVie earnings below expectations at 3.82 USD
AbbVie (ABBV) released earnings per share at 3.82 USD, compared to market expectations of 3.84 USD.
EARNINGS | Oct 30, 2026, 11:52 AM UTC
H
Abbvie Q3 2026 Earnings
Abbvie Q3 2026 Earnings
EARNINGS | Oct 26, 2026, 02:11 PM UTC
M
AbbVie reports positive Phase 3 atogepant results in menstrual migraine
Atogepant met the primary and all eight ranked secondary endpoints in the Phase 3 Luna study, according to the report.
EQUITY | Sep 10, 2026, 01:03 PM UTC
L
AbbVie Q2 2026 Earnings
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To
EARNINGS | Jul 31, 2026, 11:53 AM UTC
L
Abbvie Q2 2026 Earnings
Abbvie Q2 2026 Earnings
EARNINGS | Jul 30, 2026, 04:53 PM UTC